Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Yongwoo David Seo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-6837-5018; OpenAlex author ID A5073658575. Sources: OpenAlex.

Their work

Papers
11 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
44
Papers, trials and grants by year

2017: 2 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 11

  1. Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenoca… Co-author DOI 10.1158/0008-5472.can-25-0018↗
  2. Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer. Co-author DOI 10.1158/0008-5472.can-26-1181↗
  3. The Evolution of Oligometastatic Pancreatic Ductal Adenocarcinoma: From Anatomic Description to Biologically Informed Patient Selection. Last author DOI 10.3390/cancers18203376↗
  4. The Landmark Series: The Future of Pancreatic Cancer Clinical Trials. Co-author DOI 10.1245/s10434-024-16840-2↗
  5. Intratumoral T-cell receptor repertoire composition predicts overall survival in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1080/2162402x.2024.2320411↗
  6. Quality of superior mesenteric and hepatic artery dissection in robotic pancreatoduodenectomy for pancreatic cancer. First author DOI 10.1002/jhbp.1218↗
  7. From bugs to drugs: Bacterial 3-IAA enhances efficacy of chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.xcrm.2023.101039↗
  8. Preoperative therapy for pancreatic adenocarcinoma-precision beyond anatomy. Co-author DOI 10.1002/cncr.34273↗
  9. Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-19-0081↗
  10. T-cell programming in pancreatic adenocarcinoma: a review. Co-author DOI 10.1038/cgt.2016.66↗
  11. Long-lived pancreatic ductal adenocarcinoma slice cultures enable precise study of the immune microenvironment. First author DOI 10.1080/2162402x.2017.1333210↗

Closest collaborators

The 25 strongest of 44 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Matthew H. G. Katz · 3 shared papers, 2022–2025 · strength 0.93
  2. Douglas B. Evans · 3 shared papers, 2026 · strength 0.77
  3. Thomas B. McFall · 3 shared papers, 2026 · strength 0.77
  4. Mandana Kamgar · 3 shared papers, 2026 · strength 0.77
  5. William Adrian Hall · 2 shared papers, 2026 · strength 0.56
  6. Venu Gopal Pillarisetty · 4 shared papers, 2017–2024 · strength 0.49
  7. Rebecca Anne Snyder · 1 shared paper, 2025 · strength 0.42
  8. Nikki K. Lytle · 2 shared papers, 2026 · strength 0.41
  9. Daniel Dorbin · 2 shared papers, 2026 · strength 0.41
  10. Mohammed Aldakkak · 2 shared papers, 2026 · strength 0.41
  11. Susan Tsai · 2 shared papers, 2026 · strength 0.41
  12. G. Aaron Hobbs · 2 shared papers, 2026 · strength 0.41
  13. Razelle Kurzrock · 2 shared papers, 2026 · strength 0.41
  14. Jennifer Ann Wargo · 1 shared paper, 2023 · strength 0.39
  15. Kshitij S. Gaur · 1 shared paper, 2026 · strength 0.36
  16. Rachel A. Burge · 1 shared paper, 2026 · strength 0.21
  17. Sam Z. Thalji · 1 shared paper, 2026 · strength 0.21
  18. Ben George · 1 shared paper, 2026 · strength 0.21
  19. Beth E. Erickson · 1 shared paper, 2026 · strength 0.21
  20. Channing J. Der · 1 shared paper, 2026 · strength 0.21
  21. Kathleen K. Christians · 1 shared paper, 2026 · strength 0.21
  22. Brian F Volkman · 1 shared paper, 2026 · strength 0.20
  23. Christabelle Rajesh · 1 shared paper, 2026 · strength 0.20
  24. Graham D. Hogg · 1 shared paper, 2024 · strength 0.20
  25. William G. Hawkins · 1 shared paper, 2024 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.